Skip to main content
TipRanks
Go Ultimate75% OFF

Upstream Bio, Inc. (UPB) Stock Price & Analysis

266 Followers

UPB Stock Chart & Stats

$2.78-$0.08(-2.80%)
At close: 4:00 PM EST
$2.5$5$7.5Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$2.73 - $2.98
52-Week Range
$2.68 - $33.68
Previous Close
$2.86
Volume
N/A
Average Volume (3M)
1.32M
Market Cap
$152.38M
Enterprise Value
$82.13M
Total Cash (Recent Filing)
$207.37M
Total Debt (Recent Filing)
$789.00K
Price to Earnings (P/E)
―
Beta
1.25
Next Earnings
Mar 17, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage And Positive Equity

Minimal debt and solid positive equity provide financial flexibility relative to many development-stage biotechs. This structure reduces near-term interest and refinancing pressure, while preserving capacity to direct capital toward clinical development, although ongoing losses can still erode that support.

Defined Phase 3 Clinical Path

A defined pivotal-trial plan gives verekitug a clearer regulatory and development pathway than an earlier-stage program. Starting two placebo-controlled studies across important respiratory indications could create meaningful future product optionality if efficacy and safety are confirmed.

High Gross Margin Potential

The exceptionally high reported gross margin indicates that revenue generated to date carries substantial margin before operating expenses. If verekitug or other candidates eventually produce commercial sales, this economics profile could support attractive contribution margins, subject to successful development and launch.

Bears Say

Large And Rising Cash Burn

Heavy operating and free-cash-flow deficits show that UPB is not self-funding and must continue financing development externally. If the burn persists or rises, available resources may be depleted faster, increasing funding needs and limiting flexibility across the clinical program.

Deepening Losses And Minimal Revenue

Very small, declining revenue provides little offset to a large and expanding cost base, leaving UPB deeply unprofitable. This weak operating foundation extends the path to self-sustaining earnings and makes future financial performance highly dependent on clinical progress and eventual commercialization.

Clinical Execution And Trial Risk

The pivotal program remains exposed to execution, efficacy, safety, enrollment, and regulatory risks before it can support a commercial product. Failure to reproduce Phase 2 results or delays in the large Phase 3 studies could materially postpone revenue and increase funding requirements.

Upstream Bio, Inc. News

UPB FAQ

What was Upstream Bio, Inc.’s price range in the past 12 months?
Upstream Bio, Inc. lowest stock price was $2.68 and its highest was $33.68 in the past 12 months.
What is Upstream Bio, Inc.’s market cap?
Upstream Bio, Inc.’s market cap is $152.38M.
When is Upstream Bio, Inc.’s upcoming earnings report date?
Upstream Bio, Inc.’s next earnings report is estimated for Mar 17, 2027 (not yet confirmed), which is in 121 days.
How were Upstream Bio, Inc.’s earnings last quarter?
Upstream Bio, Inc. released its earnings results on Nov 10, 2026. The company reported -$0.75 earnings per share for the quarter, missing the consensus estimate of -$0.731 by -$0.019.
Is Upstream Bio, Inc. overvalued?
According to Wall Street analysts Upstream Bio, Inc.’s price is currently Undervalued.
Does Upstream Bio, Inc. pay dividends?
Upstream Bio, Inc. does not currently pay dividends.
What is Upstream Bio, Inc.’s EPS estimate?
Upstream Bio, Inc.’s EPS estimate is -0.70.
How many shares outstanding does Upstream Bio, Inc. have?
Upstream Bio, Inc. has 54,811,390 shares outstanding.
What happened to Upstream Bio, Inc.’s price movement after its last earnings report?
Upstream Bio, Inc. reported an EPS of -$0.75 in its last earnings report, missing expectations of -$0.731. Following the earnings report the stock price went down -5.587%.
Which hedge fund is a major shareholder of Upstream Bio, Inc.?
Hedge funds hold Upstream Bio, Inc. shares: the largest hedge-fund position in Upstream Bio, Inc. is 72,328,839 shares, and hedge funds increased their holdings by 461.1K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology